Treatment options for patients with high anti-PLA2R antibodies in primary membranous nephropathy: a single-center cohort retrospective study.

ABSTRACT:

Background

The efficacy of rituximab (RTX) in primary membranous nephropathy (PMN) patients with high titers of anti-PLA2R antibodies (aPLA2R) is controversial. This study aimed to evaluate RTX efficacy in PMN patients with high versus low aPLA2R antibodies, and to compare RTX with traditional immunosuppressive regiments in patients with high aPLA2R antibodies.

Methods

We enrolled 118 PMN patients with positive serum aPLA2R antibodies. According to baseline aPLA2R antibody levels, patients treated with RTX were classified into low-titer (L-aPLA2R-RTX) and high-titer (H-aPLA2R-RTX) groups. Meanwhile, high aPLA2R antibody patients were divided into RTX (H-aPLA2R-RTX), tacrolimus (H-aPLA2R-TAC) and cyclophosphamide (H-aPLA2R-CTX) groups according to initial therapy. All patient

SUBMITTER: Cao H 

PROVIDER: S-EPMC12801426 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature